A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Landon Brown, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Charlotte, North Carolina, United States
Landon Brown, MDRecruiting - Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
Michael McCormack, MDRecruiting - Aurora St. Luke'S Medical Center Mob
Milwaukee, Wisconsin, United States
Antony Ruggeri, MDNot, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Aug 2025
- Primary completion
- 31 Aug 2029
- Completion
- 31 Jan 2031
- Last update posted
- 2 Feb 2026
- Registered enrollment
- 35
- Registry id
- NCT06866964
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.